Prices delayed by 15 minutes
Next earnings report: 29 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Gilead Sciences, Inc. trades on Nasdaq under the ticker GILD. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks GILD has traded between 114.02 $ and 157.29 $. As of 09 October 2026 the price stood 76.45 % of the way from the 52-week low to the high.
Over one year GILD shares rose 25.96 %; over six months they rose 3.53 %. Volatility over 90 days is 27.33 %. Dividends are not included: this is price change only, as of 09 October 2026.
GILD trades at a price-to-earnings ratio of 19.8, below the sector median of 24.8. Price to sales is 6.1, above the sector median of 3.9. Price to book is 7.8, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 146.73 | 147.59 | 144.65 | 147.10 | 4M |
| 07 October 2026 | 145.28 | 148.60 | 144.85 | 146.85 | 5M |
| 06 October 2026 | 145.11 | 146.14 | 142.60 | 144.23 | 4M |
| 05 October 2026 | 143.21 | 145.16 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Gilead is built on antivirals: HIV supplies the revenue, oncology the hope for the future.
The core is HIV treatment and prevention. That is a durable market: therapy is lifelong, adherence is high, and prevention widens the population beyond those already infected. The company steadily extends the franchise's commercial life with longer-acting formulations.
The hepatitis C story is an important lesson in the company's biography: those medicines cured the disease outright, and revenue collapsed once the queue of patients was treated. A rare case where a drug's effectiveness destroyed its own market.
The replacement direction is oncology, including cell therapy after the Kite acquisition. It has not yet replaced the core income, and its progress is the main focus for investors. Gilead pays a substantial dividend.
Address:333 LAKESIDE DR, FOSTER CITY, CA, 94404, US
Gilead Sciences, Inc. reported revenue of 29.7B $ and net income of 9.2B $ over the last four quarters. Net margin is 30.99 %. Revenue changed by +3.48 % year over year. Earnings per share are 7.35 $. Market capitalisation is 182.7B $.
GILD has a return on equity of 39.19 %, above the sector median of −41.68 %. Return on assets is 16.38 %, above the sector median of −32.11 %. Operating margin is 34.88 %, above the sector median of −26.84 %.
Gilead Sciences, Inc. pays dividends quarterly: 3.25 $ per share over the past twelve months, a yield of 2.21 %. The latest payment was 0.82 $, with an ex-dividend date of 15 September 2026. The company has raised its payout for 10 years in a row.
| 409M |
| HALOHalozyme Therapeutics, Inc. | 111.70 | +1.69 % | 251M |
| BIIBBiogen Inc. | 226.01 | +3.47 % | 224M |
| TECHBio-Techne Corp | 72.46 | +0.01 % | 215M |
| KODKodiak Sciences Inc | 99.25 | +5.29 % | 214M |
| 142.79 |
| 144.63 |
| 6M |
| 02 October 2026 | 147.65 | 148.00 | 144.00 | 144.74 | 5M |
| 01 October 2026 | 149.44 | 149.44 | 147.19 | 147.50 | 4M |
| 30 September 2026 | 150.88 | 151.28 | 148.98 | 149.05 | 5M |
| 29 September 2026 | 150.18 | 152.63 | 148.79 | 151.28 | 5M |
| 28 September 2026 | 149.80 | 152.74 | 149.41 | 152.21 | 5M |
| 25 September 2026 | 150.05 | 151.00 | 148.02 | 150.93 | 5M |
| 24 September 2026 | 151.10 | 152.98 | 149.59 | 149.69 | 5M |
| 23 September 2026 | 153.60 | 154.20 | 150.06 | 151.37 | 6M |
| 22 September 2026 | 150.65 | 153.28 | 148.65 | 152.67 | 5M |
| 21 September 2026 | 150.11 | 152.10 | 148.22 | 150.56 | 6M |
| 18 September 2026 | 150.56 | 153.23 | 149.57 | 150.11 | 16M |
| 17 September 2026 | 148.78 | 151.04 | 146.89 | 150.89 | 8M |
| 16 September 2026 | 146.58 | 149.30 | 146.12 | 147.68 | 5M |
| 15 September 2026 | 144.00 | 146.35 | 142.94 | 146.30 | 5M |
| 14 September 2026 | 144.26 | 146.75 | 143.71 | 146.41 | 5M |
| 11 September 2026 | 145.24 | 145.99 | 143.50 | 143.72 | 4M |